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Abstract 
Background: To evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with 
nocturnal bruxism.
Material and Methods: Fifty subjects reporting nocturnal bruxism were recruited for a randomized clinical trial. 
Twenty five bruxers were injected with botulinum toxin in both masseters, and twenty five were treated with tra-
ditional methods of treating bruxism. Patients were evaluated at 3rd week, 2nd and 6th month and one year after 
injection and then used to calculate bruxism events. Bruxism symptoms were investigated using questionnaires.
Results: Mean pain score due to Bruxism events in the masseter muscle decreased significantly in the botulinum 
toxin injection group A (P =0.000, highly significant).  However, in the conventional treatment group, mean pain 
score does not show improvement with time (p>0.05). 
Conclusions: Our results suggest that botulinum toxin injection reduced the mean pain score and number of bruxism 
events, most likely by decreasing the muscle activity of masseter rather than affecting the central nervous system.
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Introduction
Bruxism, which includes clenching or grinding of the 
teeth, or both, affects from 50% to 95% of the adult po-
pulation (1-3). Bruxism is caused by the activation of 
reflex chewing activity. Various forms of bruxism have 
been described (4,5). The etiology of this disorder is un-
certain. Some experts believe that it is related to anxie-
ty and stress. Other explanations include asymmetry of 
teeth, and digestive and sleep disturbances. Bruxism can 
affect the muscles solely or can act as a parafunction 
that is an initiating and/or perpetuating factor in more 
involved forms of temporomandibular disorders (TMD)
involving joint damage. The treatment of bruxism in-
cludes behavioural therapy, dental appliances, and me-
dications (6-8). Many characteristics of bruxism mimic 
those of dystonia, including similar epidemiology, pain, 
and exacerbation by external factors such as fatigue, 
stress, and emotional stress. Several experts have sug-
gested that bruxism may itself be a form of focal dysto-
nia (9). If bruxism is a type of dystonia, it is possible that 
the success of the most common treatment of bruxism, 
with intraoral appliances or occlusal adjustments, may 
simply be a ‘‘sensory trick’’ that relieves dystonicsymp-
toms. Regardless of the etiology of bruxism, successful 
use of Botulinum Toxin for bruxism has been described 
(10-13). 
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According to the American Sleep Disorders Association, 
the diagnosis of nocturnal bruxism is based on the re-
ports of tooth grinding or clenching and one of the fo-
llowing signs: abnormal tooth wear, sounds associated 
with bruxism, and jaw muscle discomfort. Bruxism can 
also produce an increase in dental wear and temporo-
mandibular dysfunction. Delaying treatment, in some 
cases, may result in luxation and degenerative arthritis 
of the temporomandibular joint (14). In order to prevent 
these complications, the early diagnosis, as well as the 
appropriate treatment, is very important. The current 
therapies for this dysfunction are not totally effective. In 
lieu of this, the aim of the present study is to evaluate the 
role of botulinum toxin type A (BTX-A) in the treatment 
of pain associated with nocturnal bruxism when compa-
red to traditional methods of treatment.
Material and Methods 
A prospective, randomized, controlled, parallel group 
design study was conducted with the approbation of 
the Department of Dentistry, Alyamamah Hospital, Ri-
yadh, Saudi Arabia over the period of a year from De-
cember, 2010 to December, 2011. The study protocol 
was reviewed and approved by the Institutional Ethical 
Committee, and the Helsinki guidelines were followed. 
The procedures were explained to the patients verbally 
and in writing, and informed consent was taken before 
enrolment. Those who were not ready or fail to report 
according to the set criteria were excluded from the stu-
dy. The patients were randomly allocated to two group’s 
A. The patient reports or is aware of tooth-grinding sounds or tooth clenching during sleep.
B. One or more of the following is present:
a. Abnormal wear of teeth
b. Jaw muscle discomfort, fatigue, or pain and jaw lock upon awakening.
c. Masseter muscle hypertrophy upon voluntary forceful clenching.
C. The jaw muscle activity is not better explained by another current sleep disorder, medical or 
neurological disorder, medication use, or substance use disorder. 
Table 1. Nocturnal Bruxism Criteria according to International Classification of Sleep Disorders, Second Edition 
(ICSD-2).
i.e. experimental group I using BTX-A administration 
group and control group II that used traditional methods 
of treatment of Bruxism.
All patients (females) with bruxism associated with 
chronic pain in masseter muscles bilaterally participated 
in this study. The mean ages were 45.5± 10.8 years.
According to the diagnostic grading system of bruxism 
[Lobbezoo et al. (14)] (Table 1), all subjects underwent 
an assessment including a bruxism questionnaire (Ta-
ble 2) (i.e., oral history taking with specific focus on 
bruxism habits) plus a clinical examination to evaluate 
bruxism signs and symptoms. All patients were diagno-
sed as ‘probable’ sleep bruxism based on self-report plus 
the inspection part of a clinical examination.
The inclusion criteria for this study were as follows:
1. Moderate to severe pain in relation to the masseter 
muscles and TMJ area related to bruxism during clinical 
examination. 
2. Aged 20-60 patients. 
3. Tooth-grinding sounds corroborated by family mem-
bers or caregivers; 
4. Cases where bruxism resulted in occlusal surface at-
trition of posterior teeth; and
Exclusion criteria were pain in the orofacial region, 
insomnia, known botulinum toxin allergy, pregnancy, 
neuromuscular disease, bleeding disorders, antibiotic 
therapy, pulmonary disease that produced coughing du-
ring sleep, or infectious skin lesion at the site of the in-
jection.
The treatment plan was explained to all the study parti-
Has anyone heard you grinding your teeth at night?1. 
Is your jaw ever fatigued or sore in the morning?2. 
Are your teeth or gums ever sore on awakening in the morning?3. 
Do you ever experience temporal headaches on awakening in the morning?4. 
Are you aware of grinding your teeth during the day?5. 
Are you ever aware of clenching your teeth during the day?6. 
Table 2. Questionnaire for detecting Bruxers.
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cipants, and their consent was obtained. A total of 50 pa-
tients included in the study were randomly and equally 
divided into two groups.
Group I (25) patients underwent treatment with 20 units 
of BOTOX, (Allergan Inc.) per side was injected at three 
points into masseter muscle bilaterally (Fig. 1).
Group II (25) patients were treated with conventional 
Fig. 1. Points of application of BOTOX in the masseter muscle.
method of treating bruxism with the use of behavioural 
strategies which includes reassurance and detailed ex-
planation of the nature of the disease, occlusal splints, 
and pharmacologic measures.  
All patients had initially had a two months course of 
conservative treatment, which included reassurance and 
explanation of the nature of the problem, supplemented 
in a written format; advice on rest, soft diet, and how to 
avoid clenching; advice on the regular use of systemic 
non-steroidal anti-inflammatory drugs such as diclofe-
nac sodium (50mg bid), and the use of a lower soft bite-
raising appliance for a minimum of 8 weeks. Those who 
did not respond to conservative measures on subsequent 
review were given the following options: persevere with 
conservative measures; or have botulinum injections 
into the masseter muscle bilaterally.
Outcomes for injections were assessed using 10 cm vi-
sual analogue pain scores (VAS) at 0, 3rd week, 2 mon-
ths 6 months and 1 year. Once patients had consented to 
treatment with botulinumtoxin, they indicated their ave-
rage pain for the previous weekon a VAS sliding ruler 
for both sides of the face. They then had up to 20 units of 
BOTOX injected into masseter muscles bilaterally. All 
patients were reviewed 3 weeks after injection and then 
again recorded their average pain levels for the previous 
week using the same VAS ruler. If free from pain they 
were discharged to primary care and told to return to cli-
nic if unprecedented events occurs. We considered our 
true primaryend point to be a reduction in pain of 90% or 
more. The outcome was the proportion of patients whose 
pain had reduced at one year review, which was measu-
red by taking the difference in the four scores (VAS) as 
a percentage of the score before injection. 
All patients were evaluated at 3 weeks, 2 months, 6 
months, and 1 year. 
-Statistical analysis
Evaluation of the data was done using the statistical 
package for the social science (SPSS 17.0, Illinois, Chi-
cago) using student unpaired t- test and Wilcoxon sign 
rank test. P< 0.05 consider statistically significant. 
Results
The present study was done in order to estimate the im-
provement in pain score related to the bruxism patients 
especially in the masseter muscles, when treated with 
BOTOX and traditional methods. The results were eva-
luated using student unpaired t test and Wilcoxon sign 
rank test. 
The mean pain score pre-operatively in group I was 7.1 
± 0.72 and in group B was 7.5 ± 0.66. There was no sig-
nificant difference in mean pain score pre-operatively in 
group I and group II. Mean pain score post-operatively 
at 3 weeks in group I was 4.6 ± 0.58 and in group II 
was 5.4 ± 0.58.There was highly significant difference 
in mean pain score post-operatively at 3 weeks in group 
I and group II (p= 0.000). The mean pain score at 2nd 
month post-operatively in group I was 2.5 ± 0.59 and in 
group II was 4.3 ± 0.48. There was highly significant di-
fference in mean pain score at post-operative 2nd month 
in group I and group II. Mean pain score at 6th month 
and 1 year post-operatively in group I was 0.2 ± 0.51 and 
in group II was 2.1 ± 0.74. There was highly significant 
difference in mean pain score post-operatively at 6th 
month and 1 year in group I and group II (Tables 3,4).
Discussion
Botulinum Toxin is the most powerful known neuro-
toxin, produced by anaerobic gram-positive bacteria, 
Clostridium botulinum.This was described for the first 
time in 1817 by JC Kerner, but it was not until 1895 
that the cause of botulism was high lighted by Van Er-
mengem, and the type A toxin was finally isolated by 
Sommer in 1920. Only after the Second World War did 
work on the different forms of toxin really begin, and 
their practical application into human pathology only 
began at the end of the 1970’s with the work of Sco-
tt in the treatment of strabismus (15,16). Seven toxin 
serotypes (A to G) are currently known, only three of 
them (A, B and E) seem to be toxic to mankind. The 
toxin acts by causing a sort of chemical denervation by 
blocking neurotransmitter release at the synaptic cleft of 
the acetylcholine fibers of the motor nerves and of the 
autonomic nervous system (17). It can thus be used as a 
local acting anti-acetylcholine agent. On contrary basis, 
two other anti-acetylcholine drugs such as atropine or 
probanthine, botulinum toxin has few side effects, and 
these are always restricted to the area of injection (aller-
gic reaction ormuscular weakness) (18).
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 Pain score   
PRE OPERATIVELY Mean ± S.D t-value p-value
Group I 7 .1 ± 0.72 2.006 0.0507(NS)
Group II 7.5 ± 0.66   
    
POSTOPERATIVELY 3WEEKS    
Group I 4.6 ± 0.58 4.778 0.000**
Group II 5.4 ± 0.58   
    
POSTOPERATIVELY 2 MONTHS    
Group I 2.5 ± 0.59 11.593 0.000**
Group II 4.3 ± 0.48   
    
POSTOPERATIVELY 6 MONTHS    
Group I 0.2 ± 0.51 10.474 0.000**
Group II 2.1±0.74
POSTOPERATIVELY1YEAR
Group I 0.2 ± 0.51 10.474 0.000**
Group II 2.1±0.74
 Pain score   
PRE OPERATIVELY Mean ± S.D Z-value p-value
Group I 7 .1 ± 0.72 -1.9219 0.05486(NS)
Group II 7.5 ± 0.66   
    
POSTOPERATIVELY 3WEEKS    
Group I 4.6 ± 0.58 -3.6216 0.0003**
Group II 5.4 ± 0.58   
    
POSTOPERATIVELY 2 MONTHS    
Group I 2.5 ± 0.59 -4.2857 0.000**
Group II 4.3 ± 0.48   
    
POSTOPERATIVELY 6 MONTHS    
Group I 0.2 ± 0.51 -4.1973 0.000**
Group II 2.1±0.74
POSTOPERATIVELY 1YEAR
Group I 0.2± 0.51 -4.2857 0.000**
Group II 2.1±0.74
Table 3. Pain scores using unpaired t test at 3 weeks, 2 months, 6 months, and 1 year post-operatively.
*NS- not significant,** -Highly significant.(un paired t-test).
Table 4. Pain scores using Wilcoxon sign rank test at 3 weeks, 2 months, 6 months, and 1 year post-operatively. 
*NS- not significant,** -Highly significant.(wilcoxon sign rank test).
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Due to different taxonomies and diagnostic aspects, thre 
is some difficulty in determining an acceptable standar-
dization of diagnosis for bruxism (19). The American 
Academy of Sleep Medicine defines bruxism as astereo-
typed oral and motor sleep disorder characterized by the 
teeth grinding and tightening, while the American Acade-
my for Orofacial Pain extends the definition to the same 
movements that occur in the waking state. Intramuscular 
applications of BOTOX arean effective treatment for a 
variety of movement afflictions (20). They inhibit the 
exocytotic release of acetylcholine in the motor nerve 
terminals leading to reduced muscle contraction. This 
property makes it useful both clinically and therapeuti-
cally for a series of conditions where there is an excess 
of muscle contraction (20). Recent advances show that 
bruxism is caused by high levels of motor activity in the 
centrally situated mandible musculature, indicating that 
the reduction in muscle activity induced by the use of 
BOTOX could be beneficial in these cases (21).
The masseters were injected because they are the chief 
muscles involved in the repetitive grinding movements 
seen with bruxism (22). The other muscles of mastica-
tion (ie, temporalis, medial and lateral pterygoid, digas-
tric, and geniohyoid) were not treated so that chewing 
and swallowing could occur. This is a different approach 
from previous reports of successful bruxism treatment 
in which both the masseter and temporalis muscles were 
injected (23,24). Masseter injection alone resulted in a 
similar therapeutic response and, we believe, was easier 
to perform without the need for general anesthesia.
This suggests that the application of botulinum toxin 
type A reduces the number of bruxism events, probably 
due to diminishing of peripheral muscle activity, without 
presenting an action on the central nervous system.
It is quite interesting that how a single dose of BTX-A 
injection in the masseter muscle totally abolishes seve-
re bruxing behaviour, as depicted in our study, is con-
niving. Nonetheless, it has been hypothesized that jaw 
muscle paralysis induced by BTX A may disrupt the feed 
back loop from the trigeminal motor nucleus and inhibit 
the central bruxism generator. Alternatively, it also may 
deactivate periodontal mechano receptors during mas-
tication, which have been thought to have a facilitatory 
effect on jaw closure motor neurons (25).
Guarda-Nardini et al. (26) compared the efficacy of bo-
tulinum toxin with the saline solution in the reduction of 
pain in 20 patients with bruxism and myofascial pain in 
the masticatory muscles. The pain levels at rest and in 
mastication were evaluated through the visual analogue 
scale (VAS) in the interval of 0-10, before and after the 
application with botulinum toxin. The authors injected 
30UI of botulinum toxin type A (BOTOX®, Allergan) 
at three points in the masseter muscles and 20UI at two 
points in the anterior temporalis muscles of 10 patients 
with myofascial pain associated with bruxism, and they 
used saline solution on the remaining selected patients. 
They observed that the degree of pain reduction in mas-
tication, over the course of six months of follow-up, was 
significantly greater in the botulinum toxin group than 
in the placebo group. However, in our study we have 
injected 20 units of BOTOX in the masseter muscle bila-
terally. Moreover, the follow-up period was at 3rd week, 
2 months, 6 months and 1 year with profound impro-
vement in group I in pain as compared to the group II 
(p<0.05). 
Lee et al. (27) compared the efficacy of botulinum toxin 
with the placebo in reducing the frequency of bruxism 
events after the application (4, 8, and 12 weeks after the 
application) in 12 patients with bruxism. Those authors 
injected 80UI of botulinum toxin A (Dysport®)at three 
points in both masseter muscles in six patients, compa-
ring them with the other six patients who received appli-
cations of saline solution. They observed that the patients 
treated with botulinum toxin showed a significant reduc-
tion of the masseter muscle electromyographic activity 
and clinical improvement of bruxism, while the tempo-
ralis muscle activity was not altered. Through electrom-
yography (EMG) it was detected that the bruxism was 
significantly less frequent in the group that received bo-
tulinum toxin A than in the group that received placebo. 
Their results suggest that botulinum toxin reduces the 
number of bruxism events by reducing muscle activity, 
concluding that it is an effective treatment for nocturnal 
bruxism. Similarly, all of our patients in group I were 
treated effectively for bruxism with low dose of BOTOX 
(20 Units) per side. 
The above mentioned studies were the only randomized 
clinical trial till now available in the literature, however, 
our study is the only study on the Saudi female popu-
lation as it was tertiary referral centre for females only. 
Further, larger sample sized, meta-analysis studies are 
required to validate the findings of our study for the 
treatment of Bruxism associated with myofascial and 
TMD pain. 
Several complications after botulinum toxin injection 
into the masticatory muscles have been reported, in-
cluding mastication difficulties, muscle pain, speech 
disturbance, and unnatural facial appearance. But these 
complications are reported to be transient, usually las-
ting from 1 to 4 weeks after injection (28). Immunologic 
responses such as allergic skin reactions or formation of 
antibodies can occur in a small percentage of subjects 
(29). However, we did not observe any of these pro-
blems in our sample.
20 UI per side Botulinum toxin injection in the masseter 
muscles is an effective and safe means of intervention 
in cases of moderate to severe chronic myofascial and 
TMJ pain associated with bruxism. The patient should 
be evaluated 15 days after the application and return for 
control after three or four months after the application 
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for a new evaluation and another application, if needed. 
In this way, the treatment of bruxism with botulinum 
toxin type A can present itself as a possible treatment for 
bruxism patients. More studies are needed that follow 
the quality criteria to reach a definitive conclusion on 
safety and efficacy.
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